Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).

Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).

Item

http://www.wikidata.org/entity/Q40145206

Q40145206

about

Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

P2860

Q50063465-1A5ED8D6-4866-452B-BC3E-E9C7BA2F9F41

P2860

Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).

Item

http://www.wikidata.org/entity/Q40145206

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Substitution of nevirapine or ...... viral therapy (Nevrast study).

@en

type

Item

label

Substitution of nevirapine or ...... viral therapy (Nevrast study).

@en

prefLabel

Substitution of nevirapine or ...... viral therapy (Nevrast study).

@en

P1476

Substitution of nevirapine or ...... viral therapy (Nevrast study).

@en

P2093

Eleonora Magistrelli

http://www.w3.org/2001/XMLSchema#string

Isabella Bon

http://www.w3.org/2001/XMLSchema#string

Leonardo Calza

http://www.w3.org/2001/XMLSchema#string

Linda Bussini

http://www.w3.org/2001/XMLSchema#string

Marco Borderi

http://www.w3.org/2001/XMLSchema#string

Maria Carla Re

http://www.w3.org/2001/XMLSchema#string

Pierluigi Viale

http://www.w3.org/2001/XMLSchema#string

Vincenzo Colangeli

http://www.w3.org/2001/XMLSchema#string

P2860

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.

Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.

P304

737-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/23744235.2017.1339325

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28683645

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).

about

P2860

P2860

Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921